HRs for Parkinson’s disease among sampled patients according to sex group
| Following incidence of Parkinson’s disease | Male (n=7392) | Female (n=8420) | ||
| Pioglitazone users (n=3696) | Non-users (n=3696) | Pioglitazone users (n=4210) | Non-users (n=4210) | |
| Five-year follow-up period | ||||
| Yes, n (%) | 50 (1.35) | 49 (1.33) | 69 (1.64) | 89 (2.11) |
| Crude HR (95% CI) | 1.02 (0.69 to 1.51) | 1.00 | 0.77 (0.56 to 1.06) | 1.00 |
| Adjusted HR* (95% CI) | 1.06 (0.71 to 1.59) | 1.00 | 0.84 (0.61 to 1.15) | 1.00 |
The adjusted HR was calculated by a Cox proportional hazard regression stratified by age group and the index year.
*Adjusted for geographical region, urbanisation level, monthly income, hypertension, hyperlipidaemia, depressive disorder, insomnia, stroke, head injury, aspirin use, statins use and angiotensin receptor blockers use.